Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bisphosphonates for osteoporosis--where do we go from here?

Literature DB >> 22571168

Bisphosphonates for osteoporosis--where do we go from here?

Marcea Whitaker¹, Jia Guo, Theresa Kehoe, George Benson.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2012 PMID： 22571168 DOI： 10.1056/NEJMp1202619

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

104 in total

1. Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Authors: Jun Iwamoto; Mitsuyoshi Uzawa
Journal: Clin Rheumatol Date: 2014-11-01 Impact factor: 2.980

2. Bisphosphonate drug holidays: we reap what we sow.

Authors: S L Silverman; J D Adachi; E Dennison
Journal: Osteoporos Int Date: 2015-12-14 Impact factor: 4.507

Review 3. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

Authors: Robert A Adler; Ghada El-Hajj Fuleihan; Douglas C Bauer; Pauline M Camacho; Bart L Clarke; Gregory A Clines; Juliet E Compston; Matthew T Drake; Beatrice J Edwards; Murray J Favus; Susan L Greenspan; Ross McKinney; Robert J Pignolo; Deborah E Sellmeyer
Journal: J Bone Miner Res Date: 2016-01 Impact factor: 6.741

4. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.

Authors: Rebecca L Drieling; Andrea Z LaCroix; Shirley A A Beresford; Denise M Boudreau; Charles Kooperberg; Rowan T Chlebowski; Margery Gass; Carolyn J Crandall; Catherine R Womack; Susan R Heckbert
Journal: Menopause Date: 2016-11 Impact factor: 2.953

Bisphosphonates for osteoporosis--where do we go from here?

1. Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

2. Bisphosphonate drug holidays: we reap what we sow.

Review 3. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research.

4. Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative.

Review 5. Osteoporosis Treatment: When to Discontinue and When to Re-start.

6. New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.

7. Quality of osteoporosis care of older Medicare recipients with fragility fractures: 2006 to 2010.

Review 8. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.

9. Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films.

Review 10. Prevention and treatment of bone changes associated with exposure to glucocorticoids.